Sfoglia per Rivista CANCER TREATMENT REVIEWS
New molecular targets in bone metastases
2010-01-01 Santini, D; Galluzzo, S; Zoccoli, A; Pantano, F; Fratto, Me; Vincenzi, B; Lombardi, L; Gucciardino, C; Silvestris, N; Riva, E; Rizzo, S; Russo, A; Maiello, E; Colucci, G; Tonini, G
Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR"
2016-01-01 Sartore-Bianchi, A; Siena, S; Tonini, G; Bardelli, A; Santini, D.
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
2015-01-01 Massari, F; Santoni, M; Ciccarese, C; Santini, D; Alfieri, S; Martignoni, G; Brunelli, M; Piva, F; Berardi, R; Montironi, R; Porta, C; Cascinu, S; Tortora, G.
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
2010-01-01 Rizzo, S; Bronte, G; Fanale, D; Corsini, L; Silvestris, N; Santini, D; Gulotta, G; Bazan, V; Gebbia, N; Fulfaro, F; Russo, A
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide
2017-01-01 Del Re, M; Fogli, S; Derosa, L; Massari, F; De Souza, P; Crucitta, S; Bracarda, S; Santini, D; Danesi, R
Update on capecitabine alone and in combination regimens in colorectal cancer patients
2010-01-01 Silvestris, N; Maiello, E; De Vita, F; Cinieri, S; Santini, D; Russo, A; Tommasi, S; Azzariti, A; Numico, G; Pisconti, S; Petriella, D; Lorusso, V; Millaku, A; Colucci, G
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| New molecular targets in bone metastases | 1-gen-2010 | Santini, D; Galluzzo, S; Zoccoli, A; Pantano, F; Fratto, Me; Vincenzi, B; Lombardi, L; Gucciardino, C; Silvestris, N; Riva, E; Rizzo, S; Russo, A; Maiello, E; Colucci, G; Tonini, G | |
| Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR" | 1-gen-2016 | Sartore-Bianchi, A; Siena, S; Tonini, G; Bardelli, A; Santini, D. | |
| PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. | 1-gen-2015 | Massari, F; Santoni, M; Ciccarese, C; Santini, D; Alfieri, S; Martignoni, G; Brunelli, M; Piva, F; Berardi, R; Montironi, R; Porta, C; Cascinu, S; Tortora, G. | |
| Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? | 1-gen-2010 | Rizzo, S; Bronte, G; Fanale, D; Corsini, L; Silvestris, N; Santini, D; Gulotta, G; Bazan, V; Gebbia, N; Fulfaro, F; Russo, A | |
| The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide | 1-gen-2017 | Del Re, M; Fogli, S; Derosa, L; Massari, F; De Souza, P; Crucitta, S; Bracarda, S; Santini, D; Danesi, R | |
| Update on capecitabine alone and in combination regimens in colorectal cancer patients | 1-gen-2010 | Silvestris, N; Maiello, E; De Vita, F; Cinieri, S; Santini, D; Russo, A; Tommasi, S; Azzariti, A; Numico, G; Pisconti, S; Petriella, D; Lorusso, V; Millaku, A; Colucci, G |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile